Zurich Cantonal Bank
STRO icon

Zurich Cantonal Bank’s Sutro Biopharma STRO Stock Holding History

Zurich Cantonal Bank’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29
Closed -$1.61K – 2715
2024
Q1 		$1.61K Hold
29
– – ﹤0.01% 2662
2023
Q4 		$1.22K Sell
29
-186
-87% -$5.9K ﹤0.01% 2695
2023
Q3 		$7.45K Sell
215
-34
-14% -$1.48K ﹤0.01% 2745
2023
Q2 		$11.6K Sell
249
-65
-21% -$3.23K ﹤0.01% 2741
2023
Q1 		$14.5K Buy
+314
New +$19.9K ﹤0.01% 2783
2022
Q2 		– Sell
-874
Closed -$72K – 2928
2022
Q1 		$72K Buy
874
+625
+251% +$59.5K ﹤0.01% 2419
2021
Q4 		$37K Sell
249
-25
-9% -$4.48K ﹤0.01% 2800
2021
Q3 		$52K Buy
274
+7
+3% +$1.33K ﹤0.01% 2602
2021
Q2 		$50K Buy
267
+10
+4% +$1.96K ﹤0.01% 2450
2021
Q1 		$59K Buy
+257
New +$61K ﹤0.01% 2346

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Zurich Cantonal Bank's STRO Position: Q2 2024 in Review

Zurich Cantonal Bank sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 29 shares — an estimated $1.61K sold.

Zurich Cantonal Bank first reported a position in STRO in Q1 2021 and held it in 10 quarters. The position peaked at $72K in Q1 2022. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Zurich Cantonal Bank reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Zurich Cantonal Bank sold 29 Sutro Biopharma shares in Q2 2024, an estimated $1.61K.
  • Zurich Cantonal Bank first reported a position in Sutro Biopharma in Q1 2021 and held it in 10 quarters.
  • Zurich Cantonal Bank's Sutro Biopharma position peaked at $72K in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Zurich Cantonal Bank's 13F filing for Q2 2024, filed 29 Jul 2024.